Literature DB >> 29909029

Investigation of Drug Delivery in Rats via Subcutaneous Injection: Case Study of Pharmacokinetic Modeling of Suspension Formulations.

Po-Chang Chiang1, Karthik Nagapudi2, Peter W Fan3, Jia Liu2.   

Abstract

With the rising cost of drug research, "do more with less" has become a new emphasis in the pharmaceutical industry. Consequently, the early analysis of pharmacokinetic/pharmacodynamic, efficacy, and safety parameters for a new drug target is critical for ensuring informed decision-making as soon as possible during the drug discovery process. When absorption, distribution, metabolism, and excretion properties of compounds are suboptimal which is especially true during the early stages of drug discovery, obtaining the desired exposure can be challenging via the most common routes (oral, intravenous). Therefore, subcutaneous (SC) injection is often explored as an alternate route of delivery. Although SC injection is used widely in the industry, information about how to model and predict the absorption of drugs administered via SC injection is not readily available. In the current research, we analyzed the absorption behavior of 12 model compounds covering a wide range of physicochemical properties following SC injection. We introduced a compound-specific parameter, the absorption factor from single SC injections of suspension doses of each compound, to aid in modeling and predicting of drug absorption profiles. The pharmacokinetic models derived in this study are capable of describing and predicting the absorption properties of SC injection for individual compounds.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PK/PD; drug delivery; exposure; modeling; pharmacokinetics; subcutaneous; subcutaneous injection

Mesh:

Substances:

Year:  2018        PMID: 29909029     DOI: 10.1016/j.xphs.2018.06.003

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection.

Authors:  Cheng Deng; Qiaofeng Jin; Ya Wu; Huiling Li; Luyang Yi; Yihan Chen; Tang Gao; Wenyuan Wang; Jing Wang; Qing Lv; Yali Yang; Jia Xu; Wenpei Fu; Li Zhang; Mingxing Xie
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

2.  Thermosensitive PLGA-PEG-PLGA Hydrogel as Depot Matrix for Allergen-Specific Immunotherapy.

Authors:  Sonja Heine; Antonio Aguilar-Pimentel; Dennis Russkamp; Francesca Alessandrini; Valerie Gailus-Durner; Helmut Fuchs; Markus Ollert; Reinhard Bredehorst; Caspar Ohnmacht; Ulrich M Zissler; Martin Hrabě de Angelis; Carsten B Schmidt-Weber; Simon Blank
Journal:  Pharmaceutics       Date:  2022-07-22       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.